Azienda Sanitaria Universitaria Friuli Centrale

At Azienda Sanitaria Universitaria Friuli Centrale in Udine, a major share of the research portfolio focuses on cancer and blood disorders, with studies across neoplasms, hemic and lymphatic diseases, and related immune conditions. The trials are designed to test new treatment strategies, improve disease control, and better understand outcomes in both solid tumors and hematologic cancers.

• Follicular lymphoma, diffuse large B-cell lymphoma, mantle cell lymphoma, and peripheral T-cell lymphoma
• Multiple myeloma, acute myeloid leukemia, chronic myeloid leukemia, and myelodysplastic syndromes
• Breast, gastric, colorectal, lung, ovarian, and urothelial cancers
• Research aimed at evaluating treatment effectiveness, remission rates, and long-term disease control

The site also contributes to studies in transplant-related complications and advanced disease settings, supporting care decisions for patients with complex or hard-to-treat malignancies.

The SOC Clinica Reumatologica leads a strong program in immune system diseases, musculoskeletal diseases, and connective tissue disorders. These trials focus on conditions such as psoriatic arthritis, systemic lupus erythematosus, Sjögren’s syndrome, and systemic sclerosis, with the goal of improving symptom control and reducing disease activity.

• Psoriatic arthritis, idiopathic inflammatory myopathy, and rotator cuff tendinopathy
• Systemic lupus erythematosus, lupus nephritis, Sjögren’s syndrome, and primary Sjogren’s syndrome
• Diffuse cutaneous systemic sclerosis and related fibrotic disease
• Studies assessing new therapies for inflammation, pain, and long-term functional improvement

This research reflects a broad effort to advance treatment options for chronic inflammatory diseases that can affect daily mobility, comfort, and quality of life.

Clinical trials at this hospital also address digestive system diseases, especially Crohn’s disease and ulcerative colitis. The research is centered on finding better ways to control intestinal inflammation, support healing, and maintain remission in people living with chronic bowel disease.

• Moderately to severely active Crohn’s disease and ulcerative colitis
• Studies of mucosal and transmural healing in inflammatory bowel disease
• Primary biliary cholangitis and other liver-related immune conditions
• Trials designed to improve long-term disease management and patient-reported outcomes

These studies help expand treatment choices for patients whose symptoms remain difficult to control with standard care.

The site includes research in cardiovascular diseases, nervous system diseases, and pathological conditions linked to stroke prevention and heart failure. Trials in this area aim to reduce serious complications, improve recovery, and prevent recurrence in patients with high-risk vascular conditions.

• Heart failure, recurrent pericarditis, and acute myocardial infarction
• Prevention of ischemic stroke after acute non-cardioembolic stroke or transient ischemic attack
• Multiple sclerosis and migraine-related neurologic disorders
• Research focused on safety, prevention, and better long-term cardiovascular outcomes

This portfolio supports both acute care and prevention-focused studies for patients with complex cardiovascular and neurologic risk profiles.

A notable part of the clinical trial activity covers eye diseases, especially retinal conditions that can affect sight over time. These studies evaluate new approaches for improving vision, slowing disease progression, and maintaining visual function in chronic eye disorders.

• Diabetic macular edema and neovascular age-related macular degeneration
• Dry age-related macular degeneration and choroidal neovascularization
• Trials assessing visual acuity and treatment durability
• Research aimed at improving diagnosis and long-term vision outcomes

The focus on retinal disease shows the site’s interest in therapies that may preserve independence and daily functioning for patients with progressive vision loss.

The research program also includes bacterial infections, virus diseases, and complications related to immune suppression and transplantation. These trials explore better treatment options for serious infections and immune-mediated complications, particularly in medically complex patients.

• Invasive candidiasis, candidemia, and cytomegalovirus infection
• Graft-versus-host disease and transplant-associated complications
• Studies in patients with weakened immune systems or post-transplant immune injury
• Trials aimed at improving safety, infection control, and recovery after intensive treatment

This area reflects the site’s role in managing high-risk patients who need careful monitoring and innovative supportive care strategies.

Many trials at Azienda Sanitaria Universitaria Friuli Centrale are dedicated to solid tumors and biomarker-driven treatment selection. Research spans lung, gastric, colorectal, liver, ovarian, endometrial, cervical, melanoma, and pancreatic cancers, with a strong emphasis on evaluating targeted therapies and immunotherapy combinations.

• Non-small cell lung cancer, melanoma, gastric and gastroesophageal cancers, and colorectal cancer
• Ovarian, endometrial, cervical, hepatocellular, pancreatic, and esophageal cancers
• Studies using molecular features such as KRAS, BRAF, HER2, FGFR, and mismatch repair status
• Research focused on treatment response, recurrence prevention, and personalized cancer care

This broad oncology portfolio shows a clear interest in matching treatment to tumor biology and improving outcomes across advanced and resectable disease settings.

Beyond the larger disease groups, the site also supports studies in congenital and hereditary diseases, nutritional and metabolic diseases, and selected rare conditions. These trials often aim to improve long-term safety, symptom control, and quality of life in less common disorders.

• Mucopolysaccharidosis type II, haemophilia with inhibitors, and other rare inherited conditions
• Myelofibrosis, polycythemia vera, and other chronic marrow disorders
• Obesity-related conditions and metabolic complications
• Research designed to expand treatment options where standard therapies are limited

The diversity of this work highlights the center’s capacity to study both common and uncommon diseases across multiple specialties.